HALOZYME THERAPEUTICS, INC. (HALO) Total liabilities 2016–2025
HALOZYME THERAPEUTICS, INC. (HALO) total liabilities at each fiscal year-end, per SEC filings.
$2.5BFY2025 · since FY2016: $294.0M → $2.5B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $2.5B | +45.7% |
| FY2024 | $1.7B | +3.0% |
| FY2023 | $1.6B | -1.3% |
| FY2022 | $1.7B | +84.2% |
| FY2021 | $907.5M | +111.6% |
| FY2020 | $428.9M | -9.5% |
| FY2019 | $474.1M | +147.8% |
| FY2018 | $191.4M | -38.6% |
| FY2017 | $311.6M | +6.0% |
| FY2016 | $294.0M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More HALO financial trends
HALO RevenueHALO Net incomeHALO Net marginHALO Gross profitHALO Gross marginHALO Operating incomeHALO Operating marginHALO Operating cash flowHALO Free cash flowHALO Capital expendituresHALO Return on equityHALO Stock buybacksHALO Dividends paidHALO Total assetsHALO Shareholders’ equityHALO overview →